COMPARISON OF THE METABOLIC EFFECTS OF CARVEDILOL AND METОPROLOL IN HYPERTENSIVE PATIENTS WITH OVERWEIGHT AND OBESITY. THE CAMELLIA TRIAL

Aim. To compare two therapies based on carvedilol or metoprolol in hypertensive patients with overweight and obesity.Material and methods. 320 patients with arterial hypertension (1-2 degree) were involved in the study. 160 patients received carvedilol and 160 patients – metoprolol. Both randomized...

Full description

Saved in:
Bibliographic Details
Main Authors: S. Y. Martsevich, N. P. Kutishenko, E. V. Shilova, A. D. Deev, S. A. Shalnova, R. G. Oganov, I. A. Veliganina, E. G. Volkova, Yu. E. Voskanjan, L. I. Gapon, P Ya. Dovgalevskij, V. Ya. Ermolina, E. M. Idrisova, N. N. Ilov, A. R. Kiselev, S. Yu. Levashov, V. A. Nevzorova, G. I. Nechaeva, T. N. Panova, I. I. Reznik, V. V. Skibickij, L. A. Sokolova, V. P. Terentev, N. V. Hailo, A. V. Shabalin, T. V. Shnjukova, V. V. Yakusevich
Format: Article
Language:English
Published: Столичная издательская компания 2016-01-01
Series:Рациональная фармакотерапия в кардиологии
Subjects:
Online Access:https://www.rpcardio.online/jour/article/view/617
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849227855559393280
author S. Y. Martsevich
N. P. Kutishenko
E. V. Shilova
A. D. Deev
S. A. Shalnova
R. G. Oganov
I. A. Veliganina
E. G. Volkova
Yu. E. Voskanjan
L. I. Gapon
P Ya. Dovgalevskij
V. Ya. Ermolina
E. M. Idrisova
N. N. Ilov
A. R. Kiselev
S. Yu. Levashov
V. A. Nevzorova
G. I. Nechaeva
T. N. Panova
I. I. Reznik
V. V. Skibickij
L. A. Sokolova
V. P. Terentev
N. V. Hailo
A. V. Shabalin
T. V. Shnjukova
V. V. Yakusevich
author_facet S. Y. Martsevich
N. P. Kutishenko
E. V. Shilova
A. D. Deev
S. A. Shalnova
R. G. Oganov
I. A. Veliganina
E. G. Volkova
Yu. E. Voskanjan
L. I. Gapon
P Ya. Dovgalevskij
V. Ya. Ermolina
E. M. Idrisova
N. N. Ilov
A. R. Kiselev
S. Yu. Levashov
V. A. Nevzorova
G. I. Nechaeva
T. N. Panova
I. I. Reznik
V. V. Skibickij
L. A. Sokolova
V. P. Terentev
N. V. Hailo
A. V. Shabalin
T. V. Shnjukova
V. V. Yakusevich
author_sort S. Y. Martsevich
collection DOAJ
description Aim. To compare two therapies based on carvedilol or metoprolol in hypertensive patients with overweight and obesity.Material and methods. 320 patients with arterial hypertension (1-2 degree) were involved in the study. 160 patients received carvedilol and 160 patients – metoprolol. Both randomized groups were comparable on the main clinical characteristics.Results. By the end of the study both systolic and diastolic blood pressure (SBP, DBP) reduced in both groups р<0,0001. There were not differences of antihypertensive effect between investigated drugs (р=0,88 for SBP and р=0,61 for DBP). By the end of the study body mass index decreased by 0,52±0,10 kg/m2 (р<0,0001) in carvedilol group and by 0,26±0,10kg/m2 (р<0,01) in metoprolol group. Carvedilol in comparison with metoprolol had more positive effects on glucose (р<0,01) and lipid blood levels. By the end of the study urine acid blood level reduction was observed in carvedilol group (-16,6 μmol/l) while an increasing tendency - in metoprolol group. Carvedilol did not have negative effect on serum potassium and creatinine levels. Adverse effects rate was 6,3% in carvedilol group and 3,8% - in metoprolol group.Conclusion. The results of open, randomized CAMELLIA trial confirmed antihypertensive effect and good tolerability of carvedilol in common clinical practice as well as demonstrated some its advantages in patients with metabolic syndrome. Carvedilol has positive metabolic effects on lipid, glucose and uric acid levels. Carvedilol therapy is more preferable in patients with arterial hypertension and metabolic risk factors.
format Article
id doaj-art-3c144f61ff3e46aa865e2d37b5c826cd
institution Kabale University
issn 1819-6446
2225-3653
language English
publishDate 2016-01-01
publisher Столичная издательская компания
record_format Article
series Рациональная фармакотерапия в кардиологии
spelling doaj-art-3c144f61ff3e46aa865e2d37b5c826cd2025-08-23T10:00:21ZengСтоличная издательская компанияРациональная фармакотерапия в кардиологии1819-64462225-36532016-01-0152333810.20996/1819-6446-2009-5-2-33-38616COMPARISON OF THE METABOLIC EFFECTS OF CARVEDILOL AND METОPROLOL IN HYPERTENSIVE PATIENTS WITH OVERWEIGHT AND OBESITY. THE CAMELLIA TRIALS. Y. Martsevich0N. P. Kutishenko1E. V. Shilova2A. D. Deev3S. A. Shalnova4R. G. Oganov5I. A. VeliganinaE. G. VolkovaYu. E. VoskanjanL. I. GaponP Ya. DovgalevskijV. Ya. ErmolinaE. M. IdrisovaN. N. IlovA. R. KiselevS. Yu. LevashovV. A. NevzorovaG. I. NechaevaT. N. PanovaI. I. ReznikV. V. SkibickijL. A. SokolovaV. P. TerentevN. V. HailoA. V. ShabalinT. V. ShnjukovaV. V. YakusevichState Research Center for Preventive Medicine of RosmedtechnologyState Research Center for Preventive Medicine of RosmedtechnologyState Research Center for Preventive Medicine of RosmedtechnologyState Research Center for Preventive Medicine of RosmedtechnologyState Research Center for Preventive Medicine of RosmedtechnologyState Research Center for Preventive Medicine of RosmedtechnologyAim. To compare two therapies based on carvedilol or metoprolol in hypertensive patients with overweight and obesity.Material and methods. 320 patients with arterial hypertension (1-2 degree) were involved in the study. 160 patients received carvedilol and 160 patients – metoprolol. Both randomized groups were comparable on the main clinical characteristics.Results. By the end of the study both systolic and diastolic blood pressure (SBP, DBP) reduced in both groups р<0,0001. There were not differences of antihypertensive effect between investigated drugs (р=0,88 for SBP and р=0,61 for DBP). By the end of the study body mass index decreased by 0,52±0,10 kg/m2 (р<0,0001) in carvedilol group and by 0,26±0,10kg/m2 (р<0,01) in metoprolol group. Carvedilol in comparison with metoprolol had more positive effects on glucose (р<0,01) and lipid blood levels. By the end of the study urine acid blood level reduction was observed in carvedilol group (-16,6 μmol/l) while an increasing tendency - in metoprolol group. Carvedilol did not have negative effect on serum potassium and creatinine levels. Adverse effects rate was 6,3% in carvedilol group and 3,8% - in metoprolol group.Conclusion. The results of open, randomized CAMELLIA trial confirmed antihypertensive effect and good tolerability of carvedilol in common clinical practice as well as demonstrated some its advantages in patients with metabolic syndrome. Carvedilol has positive metabolic effects on lipid, glucose and uric acid levels. Carvedilol therapy is more preferable in patients with arterial hypertension and metabolic risk factors.https://www.rpcardio.online/jour/article/view/617arterial hypertensionoverweightobesitybeta-blockerscarvedilolmetoprolol
spellingShingle S. Y. Martsevich
N. P. Kutishenko
E. V. Shilova
A. D. Deev
S. A. Shalnova
R. G. Oganov
I. A. Veliganina
E. G. Volkova
Yu. E. Voskanjan
L. I. Gapon
P Ya. Dovgalevskij
V. Ya. Ermolina
E. M. Idrisova
N. N. Ilov
A. R. Kiselev
S. Yu. Levashov
V. A. Nevzorova
G. I. Nechaeva
T. N. Panova
I. I. Reznik
V. V. Skibickij
L. A. Sokolova
V. P. Terentev
N. V. Hailo
A. V. Shabalin
T. V. Shnjukova
V. V. Yakusevich
COMPARISON OF THE METABOLIC EFFECTS OF CARVEDILOL AND METОPROLOL IN HYPERTENSIVE PATIENTS WITH OVERWEIGHT AND OBESITY. THE CAMELLIA TRIAL
Рациональная фармакотерапия в кардиологии
arterial hypertension
overweight
obesity
beta-blockers
carvedilol
metoprolol
title COMPARISON OF THE METABOLIC EFFECTS OF CARVEDILOL AND METОPROLOL IN HYPERTENSIVE PATIENTS WITH OVERWEIGHT AND OBESITY. THE CAMELLIA TRIAL
title_full COMPARISON OF THE METABOLIC EFFECTS OF CARVEDILOL AND METОPROLOL IN HYPERTENSIVE PATIENTS WITH OVERWEIGHT AND OBESITY. THE CAMELLIA TRIAL
title_fullStr COMPARISON OF THE METABOLIC EFFECTS OF CARVEDILOL AND METОPROLOL IN HYPERTENSIVE PATIENTS WITH OVERWEIGHT AND OBESITY. THE CAMELLIA TRIAL
title_full_unstemmed COMPARISON OF THE METABOLIC EFFECTS OF CARVEDILOL AND METОPROLOL IN HYPERTENSIVE PATIENTS WITH OVERWEIGHT AND OBESITY. THE CAMELLIA TRIAL
title_short COMPARISON OF THE METABOLIC EFFECTS OF CARVEDILOL AND METОPROLOL IN HYPERTENSIVE PATIENTS WITH OVERWEIGHT AND OBESITY. THE CAMELLIA TRIAL
title_sort comparison of the metabolic effects of carvedilol and metоprolol in hypertensive patients with overweight and obesity the camellia trial
topic arterial hypertension
overweight
obesity
beta-blockers
carvedilol
metoprolol
url https://www.rpcardio.online/jour/article/view/617
work_keys_str_mv AT symartsevich comparisonofthemetaboliceffectsofcarvedilolandmetoprololinhypertensivepatientswithoverweightandobesitythecamelliatrial
AT npkutishenko comparisonofthemetaboliceffectsofcarvedilolandmetoprololinhypertensivepatientswithoverweightandobesitythecamelliatrial
AT evshilova comparisonofthemetaboliceffectsofcarvedilolandmetoprololinhypertensivepatientswithoverweightandobesitythecamelliatrial
AT addeev comparisonofthemetaboliceffectsofcarvedilolandmetoprololinhypertensivepatientswithoverweightandobesitythecamelliatrial
AT sashalnova comparisonofthemetaboliceffectsofcarvedilolandmetoprololinhypertensivepatientswithoverweightandobesitythecamelliatrial
AT rgoganov comparisonofthemetaboliceffectsofcarvedilolandmetoprololinhypertensivepatientswithoverweightandobesitythecamelliatrial
AT iaveliganina comparisonofthemetaboliceffectsofcarvedilolandmetoprololinhypertensivepatientswithoverweightandobesitythecamelliatrial
AT egvolkova comparisonofthemetaboliceffectsofcarvedilolandmetoprololinhypertensivepatientswithoverweightandobesitythecamelliatrial
AT yuevoskanjan comparisonofthemetaboliceffectsofcarvedilolandmetoprololinhypertensivepatientswithoverweightandobesitythecamelliatrial
AT ligapon comparisonofthemetaboliceffectsofcarvedilolandmetoprololinhypertensivepatientswithoverweightandobesitythecamelliatrial
AT pyadovgalevskij comparisonofthemetaboliceffectsofcarvedilolandmetoprololinhypertensivepatientswithoverweightandobesitythecamelliatrial
AT vyaermolina comparisonofthemetaboliceffectsofcarvedilolandmetoprololinhypertensivepatientswithoverweightandobesitythecamelliatrial
AT emidrisova comparisonofthemetaboliceffectsofcarvedilolandmetoprololinhypertensivepatientswithoverweightandobesitythecamelliatrial
AT nnilov comparisonofthemetaboliceffectsofcarvedilolandmetoprololinhypertensivepatientswithoverweightandobesitythecamelliatrial
AT arkiselev comparisonofthemetaboliceffectsofcarvedilolandmetoprololinhypertensivepatientswithoverweightandobesitythecamelliatrial
AT syulevashov comparisonofthemetaboliceffectsofcarvedilolandmetoprololinhypertensivepatientswithoverweightandobesitythecamelliatrial
AT vanevzorova comparisonofthemetaboliceffectsofcarvedilolandmetoprololinhypertensivepatientswithoverweightandobesitythecamelliatrial
AT ginechaeva comparisonofthemetaboliceffectsofcarvedilolandmetoprololinhypertensivepatientswithoverweightandobesitythecamelliatrial
AT tnpanova comparisonofthemetaboliceffectsofcarvedilolandmetoprololinhypertensivepatientswithoverweightandobesitythecamelliatrial
AT iireznik comparisonofthemetaboliceffectsofcarvedilolandmetoprololinhypertensivepatientswithoverweightandobesitythecamelliatrial
AT vvskibickij comparisonofthemetaboliceffectsofcarvedilolandmetoprololinhypertensivepatientswithoverweightandobesitythecamelliatrial
AT lasokolova comparisonofthemetaboliceffectsofcarvedilolandmetoprololinhypertensivepatientswithoverweightandobesitythecamelliatrial
AT vpterentev comparisonofthemetaboliceffectsofcarvedilolandmetoprololinhypertensivepatientswithoverweightandobesitythecamelliatrial
AT nvhailo comparisonofthemetaboliceffectsofcarvedilolandmetoprololinhypertensivepatientswithoverweightandobesitythecamelliatrial
AT avshabalin comparisonofthemetaboliceffectsofcarvedilolandmetoprololinhypertensivepatientswithoverweightandobesitythecamelliatrial
AT tvshnjukova comparisonofthemetaboliceffectsofcarvedilolandmetoprololinhypertensivepatientswithoverweightandobesitythecamelliatrial
AT vvyakusevich comparisonofthemetaboliceffectsofcarvedilolandmetoprololinhypertensivepatientswithoverweightandobesitythecamelliatrial